Q-omics provides the consensus-scored RRP9 profile across patient tissues and cancer cell-line models. RRP9 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, RRP9 is differentially expressed in 16, with the highest sampling consensus in COAD. Additionally, RRP9 protein abundance shows 27,747 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight LIHC, COAD, and GBM as cancer lineages where RRP9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RRP9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RRP9 survival associations across molecular data types. RRP9 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (2) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RRP9 RNA expression–survival associations across cancer types. High RRP9 expression shows unfavorable associations in LIHC, ACC, KIRC and SARC, but favorable associations in UVM and SCLC. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for RRP9 RNA expression.
This table summarizes RRP9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRP for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for RRP9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RRP9 shows higher tumor expression in COAD, KIRP, BLCA, STAD, LIHC and HNSC. The COAD box plot shows higher RRP9 RNA expression in tumor versus normal tissue (log2 FC = +1.956, t-test p < 0.001).
This table shows molecular features associated with RRP9 in patient tissues and cancer cell lines. In patient samples, RRP9 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, RRP9 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BLOOD_Lymphoma.
